CXCL10 and rheumatoid arthritis: Specifically, suppression of the TNF-IRF1-IFNβ-induced secretion of IP-10 and BAFF by tofacitinib might decrease the IP-10-driven recruitment of T cells into the inflamed RA synovium and the BAFF-dependent proliferation, differentiation and antibody production by B cells.